Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-05-23
2000-01-18
Krass, Frederick
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514 2, 514 8, 514 42, 514 44, 514 62, 514 80, 514255, 514383, 514398, 514399, 514400, 514561, 514562, 514563, 514564, 514566, 514638, 514663, 514667, 514673, 514674, 514851, 514311, 514312, 514313, A01N 4350, A01N 3302, A61K 31415, A61K 3113
Patent
active
06015828&
ABSTRACT:
This invention relates generally to medical treatment methods. Specifically, the invention relates to methodology for the correction of defective chloride transport by activation of chloride channels of the lung and other epithelia using genetic or chemical modification. These methods relate to the treatment of epithelia with compounds which cause activation of the channel as measured by increased probability (Po) of opening of the channel at physiologically relevant holding potentials. These methods also relate to the treatment of epithelia with gene therapy to introduce chloride channels genes with site mutations which cause activation of the channel as measured by increased probability (Po) of opening of the channel at physiologically relevant holding potentials. These treatments will reduce life-threatening complications frequently found in diseases such as cystic fibrosis. These methods of activation of chloride channels also comprise treatment of chloride channels with amidation reactions.
REFERENCES:
patent: 3193523 (1965-07-01), Neumann et al.
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 4937270 (1990-06-01), Hamilton et al.
patent: 5240846 (1993-08-01), Collins et al.
patent: 5242947 (1993-09-01), Cherksey et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5503989 (1996-04-01), Bibbs et al.
patent: 5504241 (1996-04-01), Pohl et al.
patent: 5674898 (1997-10-01), Cheng et al.
patent: 5877179 (1999-03-01), Pollard et al.
Luis P.Cid, et al., Human Molecular Genetics, 1995, vol. 4, No. 3 pp. 407-413.
Michael J. Welsh, et al, 1992, Neuron, vol. 8, pp. 821-829.
Eduardo F. Tizzano et al., 1992, The Journal of Pediatrics, vol. 120, No. 3, pp. 337-349.
Thomas F. Boat, et al., `Cystic Fibrosis`, The Metabolic Basis of Inherited Disease (1989) Chapter 108, pp. 2649-2680.
Michael R. Knowles, M.D. et al., , Apr., 26, 1990, The New England Journal of Medicine, vol. 322, No. 17, pp. 1189-1194.
Thomas J. Jentsch, 1996, Current Opinion in Neurobiology, pp. 303-310.
Danuta H. Malinowski et al., 1995, the American Physiological Society, 0363-6143/95, pp. C191-C-200.
Thomas J. Jentsch, et al.1995, Journal of Physiology, 482.P, pp. 19S-25S.
LandOfFree
Chemical modification of chloride channels as a treatment for cy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemical modification of chloride channels as a treatment for cy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemical modification of chloride channels as a treatment for cy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-563823